Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201's Unique Pulsatile Mechanism of Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 21 2024
0mins
Should l Buy ?
Source: Newsfilter
Lumos Pharma's Clinical Trials: Lumos Pharma presented new data from its Phase 2 clinical trials for LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD), at the ESPE 2024 meeting, showing sustained growth and significant increases in height velocity and hormone levels over 24 months.
Future Developments: The company plans to advance LUM-201 into a Phase 3 clinical trial next year, aiming to transform the growth hormone market from injectable to oral therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
